Treatment of osteoporosis in men. (Q35895418)

11 August 2017

1 reference

title

Treatment of osteoporosis in men. (English)

1 reference

11 August 2017

0 references

Orwoll ES

1

1 reference

PubMed ID

15383924

11 August 2017

language of work or name

English

0 references

publication date

29 July 2004

1 reference

Calcified Tissue International

11 August 2017

1 reference

11 August 2017

75

1 reference

11 August 2017

2

1 reference

11 August 2017

114-119

1 reference

https://scigraph.springernature.com/pub.10.1007/s00223-004-0288-5

11 August 2017

0 references

cites work

Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0288-5

Effect of alendronate on bone mineral density in male idiopathic osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0288-5

Alendronate Treatment in Men With Primary Osteoporosis: A Three-Year Longitudinal Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0288-5

Effects of alendronate on bone density in men with primary and secondary osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0288-5

Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0288-5

Treatment of male osteoporosis: recent advances with alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0288-5

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0288-5

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0288-5

Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0288-5

The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0288-5

Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0288-5

Long-term effect of testosterone therapy on bone mineral density in hypogonadal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0288-5

Testosterone replacement therapy improves mood in hypogonadal men--a clinical research center study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0288-5

Effect of testosterone treatment on bone mineral density in men over 65 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0288-5

Clinical review 144: Estrogen and the male skeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0288-5

Avoidance of vertebral fractures in men with idiopathic osteoporosis by a three year therapy with calcium and low-dose intermittent monofluorophosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0288-5

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0288-5

Time for (more research on) testosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0288-5

Alendronate for the Treatment of Osteoporosis in Men

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0288-5

10.1007/S00223-004-0288-5

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15383924